Okere AN, Montesdeoca J, Glasper A, Diaby V
There are currently no FDA-approved or regulated patches that contain GLP-1 medications like semaglutide or terzepatide
NICE guidance recommends considering these medications for specific clinical scenarios where multiple metabolic abnormalities coexist
A safer sequence is to reduce ongoing exposure, restore hydration and nutrition, correct bowel dysfunction, evaluate organ safety, address biochemical deficiencies and then retest before escalating treatment
And technically it should be cheaper to manufacture pills compared to injections. Finally, Amy Sheer, MD, MPH, DABOM, associate professor of medicine and program director of the Obesity Medicine Fellowship at the University of Florida also not involved in this research told MNT that more competition is a good thing in the world of GLP-1s, hopefully driving down the cost and adding to the overall safety profile of GLP1 drugs